News

Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases, and to help ensure people have access to

Ankylosing spondylitis is a painful and progressive type of arthritis, in which some or all of the joints and bones of the spine fuse together. The disease is

The Series C round was led by Deerfield Management while RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors and others made significant new investments in the gene therapy

SB26, also known as TAK-671, is a ulinastatin-Fc (UTI-Fc) fusion protein intended to treat severe acute pancreatitis. Non-clinical GLP safety studies performed in monkeys and rats supported early

This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N- Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in

Aralez has signed an agreement to sell its VIMOVO royalties and Canadian operations to Nuvo Pharmaceuticals for $110m. In another deal, the company agreed to offload its TOPROL-XL

Onpattro is claimed to be the first-of-its-kind RNAi therapeutic and only FDA-approved treatment for this indication. Earlier, Onpattro secured breakthrough therapy and orphan drug designations from the FDA.

The financing was led by Novo Holdings and joined by new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed by Tekla Capital Management. Existing investors Versant Ventures,

Millendo is engaged in the development of novel treatments for orphan endocrine diseases. The combined company will further advance Millendo’s pipeline of transformative treatments for orphan endocrine diseases.